Shanxi C&Y Pharmaceutical Group (300254.SZ) disclosed its 2024 interim report, with the company's reported revenue reaching 4...
According to the Zhitong Finance APP, Shanxi C&Y Pharmaceutical Group (300254.SZ) disclosed its 2024 interim report. The company achieved operating income of 0.401 billion yuan, a year-on-year growth of 9.72%. The net income attributable to shareholders of the listed company was 33.5025 million yuan, and the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.0552 million yuan, turning losses into profits year-on-year. The basic earnings per share is 0.1387 yuan per share.
